Ana Jiménez-Ubieto

ELM-2: dynamiek van complete responsen bij odronextamab bij recidief of refractair folliculair lymfoom

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, r...

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymp...

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.

IMWG responscriteria validatie bij myeloom: PETHEMA/GEM2012MENOS65